Adverse Effects Profile of Dicycloplatin (DCP) Offers Chemotherapeutic Advantage Over Cisplatin and Carboplatin.

导出原文传递

翻译打印收藏纠错

作者： Jing Jie,Yu ^[1] ; Thomas,Hogan ^[2] ; Chad,Morley ^[3] ; Chad,Crigger ^[3] ; Shunchang,Jiao ^[4] ; Dorian J,Williams ^[5] ; Mohamad W,Salkini ^[3] ; Xuqing,Yang ^[6] ; Xiaobing,Liang ^[7] ; Bingxue,Yan ^[7] ; Courtney,Cecil ^[8] ; Ava C,Winn ^[9] ; Jenny,Zheng ^[7] ; Y I,Guo ^[7] ; Bing-Hua,Jiang ^[10] ; Ida M,Washington ^[8]

作者单位： Department of Biochemistry, School of Medicine, School of Pharmacy, WVU Cancer Institute, Morgantown, WV, U.S.A. jyu@hsc.wvu.edu yujingjie@hotmail.com. ^[1] Department of Medicine, School of Medicine, West Virginia University, Morgantown, WV, U.S.A. ^[2] Department of Urology, School of Medicine, West Virginia University, Morgantown, WV, U.S.A. ^[3] Oncology Department of Internal Medicine, PLA General Hospital, Beijing, P.R. China. ^[4] Department of Family Medicine, School of Medicine, West Virginia University, Morgantown, WV, U.S.A. ^[5] Department of Chemistry, Peking University and Beijing Xingda Scientific System Company, Beijing, P.R. China. ^[6] Department of Biochemistry, School of Medicine, School of Pharmacy, WVU Cancer Institute, Morgantown, WV, U.S.A. ^[7] Office of Laboratory Animal Resources, West Virginia University, Morgantown, WV, U.S.A. ^[8] Molecular Biology Core Facility, National Institute for Occupational Safety and Health, CDC, Morgantown, WV, U.S.A. ^[9] Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, U.S.A. ^[10]

关键词 Chemotherapy dicycloplatin (DCP)therapeutic advance tolerable side effects